Bioverativ (BIVV) Stock Price, News & Analysis

Company Overview

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Key Stats

• Today's Range: $104.98 to $104.98
• 50-Day Range: $104.98 to $104.98
• 52-Week Range: $48.14 to $105.01
• Volume: N/A
• Average Volume: 3.03 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIVV Stock Analysis - Frequently Asked Questions

How were Bioverativ's earnings last quarter?

Bioverativ Inc. (NASDAQ:BIVV) posted its quarterly earnings data on Thursday, October, 26th. The biotechnology company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.25. The firm's quarterly revenue was up 27.2% compared to the same quarter last year.

What other stocks do shareholders of Bioverativ own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioverativ investors own include Rexford Industrial Realty (REXR), Biogen (BIIB), Spark Therapeutics (ONCE), Bristol-Myers Squibb (BMY), Phillips 66 (PSX), Gilead Sciences (GILD) and Marinus Pharmaceuticals (MRNS).

Company Calendar

• Last Earnings: 10/26/2017
• Today: 12/21/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BIVV
• CUSIP: N/A
• CIK: 1681689
• Web: www.bioverativ.com
• Phone: +1-781-6634400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A